Cases
Tetraphase Pharmaceuticals, Inc.
Securities Class Action
Overview
Overview
- Date:
- 5/9/2016
- Company Name:
- Tetraphase Pharmaceuticals, Inc.
- Stock Symbol:
- TTPH
- Status:
- Closed/Complete
NEW YORK, May 9, 2016 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) investors concerning whether the company’s board of directors violated their fiduciary duties.
The investigation concerns whether the company's board of directors and its officers complied with their legal obligations to the company and its shareholders in connection with misrepresentations regarding the efficacy and safety of Eravacycline, and attendant capacity for approval by both the U.S. Food and Drug Administration and the European Medicines Agency.
If you purchased Tetraphase securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
The investigation concerns whether the company's board of directors and its officers complied with their legal obligations to the company and its shareholders in connection with misrepresentations regarding the efficacy and safety of Eravacycline, and attendant capacity for approval by both the U.S. Food and Drug Administration and the European Medicines Agency.
If you purchased Tetraphase securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.